Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

19.25 +0.43 (+2.26%)
Streaming Delayed Price Updated: 9:53 AM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Erasca, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Securities Class Action Filed Against Erasca, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
News headline image
Rosen Law Firm Urges Erasca, Inc. (NASDAQ: ERAS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Erasca (NASDAQ:ERAS) Beats Q1 Estimates on Promising ERAS-0015 Data ↗
Via Chartmill
News headline image
ERAS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Erasca (ERA) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. (NASDAQ:ERAS) on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.
From Kirby McInerney LLP
Via Business Wire
News headline image
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions. 
Via The Motley Fool
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference ↗
Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and... 
Via MarketBeat
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
From Pomerantz LLP
Via GlobeNewswire
News headline image
ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial ↗
Today, April 28, 2026, investors are weighing how a trial death will reshape Erasca's investment thesis. 
Via The Motley Fool
Topics Stocks
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.